Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

430

Employees430

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

430

Employees430

ARVN Key Statistics

Market cap

558.71M

Market cap558.71M

Price-Earnings ratio

-1.47

Price-Earnings ratio-1.47

Dividend yield

—

Dividend yield—

Average volume

1.54M

Average volume1.54M

High today

$7.85

High today$7.85

Low today

$7.80

Low today$7.80

Open price

$7.71

Open price$7.71

Volume

23.72K

Volume23.72K

52 Week high

$29.61

52 Week high$29.61

52 Week low

$5.90

52 Week low$5.90

ARVN News

TipRanks 51m

Arvinas price target lowered to $14 from $16 at Stephens

Stephens analyst Sudan Loganathan lowered the firm’s price target on Arvinas (ARVN) to $14 from $16 and keeps an Overweight rating on the shares after the compa...

Seeking Alpha 5h

Arvinas announces $100M share repurchase program

Arvinas announces $100M share repurchase program Sep. 18, 2025 2:13 AM ET Arvinas, Inc. (ARVN) Stock By: Akanksha Khushi, SA News Editor 5 Share Save Play ( <...

TipRanks 15h

Arvinas Announces 15% Workforce Reduction and Cost Savings

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

56%

of 18 ratings

Buy

55.6%

Hold

44.4%

Sell

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.